WEREWOLF THERAPEUTICS INC
1 day chart
Werewolf Therapeutics, Inc. is a biopharmaceutical company focused on developing a pipeline of cancer treatments. The Company is developing immuno-stimulatory therapeutics designed to act selectively within the tumor microenvironment to enhance the body’s immune response to cancer. The Company’s product candidates include WTX-124, WTX-330 and WTX-613. The Company’s advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12). Its INDUKINE molecules for the treatment of solid tumors. The Company initiating a Phase I/Ib clinical trial for each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. WTX-613 is designed to have minimal activity in the periphery and is activated preferentially in the tumor microenvironment (TME) to release wild-type IFNα in the tumor and potentially stimulate an anti-tumor immune response.
Buy US stocks in Australia with $0 brokerage and trade HOWL today!
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.